Abviva to receive patent for its new Mammastatin technology

Abviva, Inc. (Pink Sheets: ABVV), a biomedical company engaged in the development and commercialization of breast cancer-related applications of Mammastatin, announced that the Canadian Patent Office issued notice that it will be issuing patent application Number 2.267.095 within 12 weeks.

The Mammastatin technology continues to increase its protection as evidenced by the granting of patents around its core technology.  In recent months, the Japanese Patent Office issued two patents on the Mammastatin technology, and the Canadian patent will help protect the technology when it begins international expansion.

"The Company is very pleased with this notice of patent to be granted and believes that the issuance of the many patents will allow Abviva to expand internationally in years to come," said Barrett Evans, Abviva's CEO.